Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.
Poggio F, Ceppi M, Lambertini M, Bruzzi P, Ugolini D, Bighin C, Levaggi A, Giraudi S, D'Alonzo A, Vaglica M, Blondeaux E, Sertoli MR, Pronzato P, Del Mastro L. Poggio F, et al. Among authors: vaglica m. Breast. 2017 Jun;33:104-108. doi: 10.1016/j.breast.2017.03.011. Epub 2017 Mar 27. Breast. 2017. PMID: 28360014 Review.
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study.
Lambertini M, Fontana V, Massarotti C, Poggio F, Dellepiane C, Iacono G, Abate A, Miglietta L, Ferreccio C, Pescio MC, Conte B, Blondeaux E, Bighin C, D'Alonzo A, Vaglica M, Zanardi E, Boccardo F, Ballestrero A, Anserini P, Del Mastro L. Lambertini M, et al. Among authors: vaglica m. Breast. 2018 Oct;41:51-56. doi: 10.1016/j.breast.2018.06.012. Epub 2018 Jun 22. Breast. 2018. PMID: 30007268
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study.
Bighin C, Dozin B, Poggio F, Ceppi M, Bruzzi P, D'Alonzo A, Levaggi A, Giraudi S, Lambertini M, Miglietta L, Vaglica M, Fontana V, Iacono G, Pronzato P, Del Mastro L. Bighin C, et al. Among authors: vaglica m. Oncotarget. 2017 Jul 4;8(27):44800-44810. doi: 10.18632/oncotarget.14735. Oncotarget. 2017. PMID: 28108743 Free PMC article.
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Palmeri S, Vaglica M, Spada S, Filippelli G, Farris A, Palmeri L, Massidda B, Misino A, Ferraù F, Comella G, Leonardi V, Condemi G, Mangiameli A, De Cataldis G, Macaluso MC, Cajozzo M, Iannitto E, Danova M. Palmeri S, et al. Among authors: vaglica m. Oncology. 2005;68(4-6):438-45. doi: 10.1159/000086986. Epub 2005 Jul 14. Oncology. 2005. PMID: 16020974 Free article. Review.
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study.
Palmeri S, Lorusso V, Palmeri L, Vaglica M, Porta C, Nortilli R, Ferraú F, Comella G, Massidda B, Danova M; Carcinomas of Unknown Primary Italian Study Group. Palmeri S, et al. Among authors: vaglica m. Cancer. 2006 Dec 15;107(12):2898-905. doi: 10.1002/cncr.22379. Cancer. 2006. PMID: 17109447 Free article. Clinical Trial.
20 results